FMS Stock Analysis: Buy, Sell, or Hold?
FMS - Fresenius Medical Care AG
$23.10
-0.17 (-0.73%)
▼
5d:
-1.41%
30d:
-10.12%
90d:
+7.09%
HOLD
LOW Confidence
Analysis Updated: Aug 28, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When FMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: FMS is fairly valued with market pricing in 1.5% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: FMS is fairly valued with market pricing in 1.5% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$42.85
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$26.61
13.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FMS is currently trading at $23.10, which is considered oversold relative to its 30-day fair value range of $23.43 to $24.79. The stock's valuation (Forward PE: 7.3) is in line with its historical norms (7.0). At these levels, the market is pricing in 1.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FMS is in a uptrend. The price is currently testing key support at $22.91. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FMS scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $25.89 (+12.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FMS is in a uptrend. The price is currently testing key support at $22.91. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FMS scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $25.89 (+12.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$23.43 -
$24.79
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($25.89)
- NEUTRAL: Market pricing in 1.5% annual earnings growth - fairly valued
- CAUTION: Bottoming setup, but lagging the sector by 12% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$23.43 -
$24.79
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$22.91
Resistance Level
$24.04
Current Trend
Uptrend
Technical data as of
Aug 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.35
Wall Street Target
$25.89
(+12.1%)
Revenue Growth (YoY)
1.4%
Earnings Growth (YoY)
5.5%
Profit Margin
4.8%
Valuation Premium vs History
+1.5% premium
PE vs Historical
7.4 vs 7.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.5%
(market-implied from PE analysis)
1-Year Target
$23.45
(+2%)
2-Year Target
$23.80
(+3%)
3-Year Target
$24.16
(+5%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$23.01
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 52.1%)
$212.95
(+822%)
Base:
(SPY PE: 7.3, Growth: 52.1%)
$77.96
(+238%)
Bear:
(PE: 6.2, Growth: 52.1%)
$66.27
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 12.06 | Current EPS (TTM): $1.93
Bull Case
$41.70
(+81%)
Analyst growth 62.9%, PE expands to 13.3
Base Case
$37.90
(+64%)
Market implied 62.9%, PE stable at 12.1
Bear Case
$15.82
(-32%)
Severe decline -20.0%, PE contracts to 10.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 30, 2026 4:59 AM ET
Data refreshes hourly during market hours. Next update: 5:59 AM
Data refreshes hourly during market hours. Next update: 5:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FMS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$282 | 45 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$451 | 44 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$148 | 51 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$24 | 43 HOLD |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
11 analysts |
$135 | 49 HOLD |
